AbbVie settles trade secrets fight with Evolus, scoring $35M and royalties on Botox rival Jeuveau
AbbVie’s newest revenue streams come courtesy of Evolus and its Botox competitor Jeuveau. To settle a long-running legal battle, Evolus will pay Allergan and its partner Medytox $ 35 million in cash, plus royalties on Jeuveau’s U.S. sales, according an Evolus SEC filing. The settlement ends all legal claims the trio had levied against one another… Read More »